VKTX Stock Recent News
VKTX LATEST HEADLINES
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
Viking recently announced the results of an early-stage clinical trial for VK0214.
Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
We could be witnessing the birth of a major player in the biotech industry.
It's hard to go wrong with either company, but one is more appealing.
This company is operating in one of today's hottest markets.
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.
Viking, which is also developing a weight-loss pill, has a buy rating from all 13 analysts offering coverage.
Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRβ), in patients with X-linked adrenoleukodystrophy (X-ALD). Results from this study showed VK0214 to be safe and well-tolerated following once-daily dosing over the 28-day study period.